Login to Your Account



BioXell Shares Plunge on Elocalcitol Miss

By Cormac Sheridan


Wednesday, April 15, 2009
BioXell SpA suffered a collapse in its share price following news that its vitamin D3 analogue elocalcitol failed to meet the primary endpoint of a Phase IIb trial in overactive bladder (OAB). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription